Results 11 to 20 of about 17,216 (186)
Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
Open Access Rheumatology: Research and Reviews, 2012 Miho Murakami,1 Minako Tomiita,2,3 Norihiro Nishimoto11Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, 2Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, 3Department of Allergy and Rheumatology, Chiba
Murakami M, Tomiita M, Nishimoto N
doaj +5 more sources
Systemic-onset juvenile idiopathic arthritis
Autoimmunity Reviews, 2016 Systemic-onset juvenile idiopathic arthritis (SoJIA) is a systemic inflammatory disease which has up to now been classified as a category of juvenile idiopathic arthritis. However, in this context, systemic inflammation has been associated with dysregulation of the innate immune system, suggesting that it may rather be part of the spectrum of ...
Rolando Cimaz
exaly +5 more sources
Extracellular vesicles in systemic juvenile idiopathic arthritis. [PDF]
J Leukoc Biol, 2023 Abstract Systemic juvenile idiopathic arthritis is a chronic pediatric inflammatory disease of unknown etiology, characterized by fever, rash, hepatosplenomegaly, serositis, and arthritis. We hypothesized that intercellular communication, mediated by extracellular vesicles, contributes to systemic juvenile idiopathic arthritis ...
Maller J +8 more
europepmc +3 more sources
JAK inhibitors in systemic juvenile idiopathic arthritis
Frontiers in Pediatrics, 2023 ObjectiveSystemic juvenile idiopathic arthritis (SJIA) is characterized by excessive and inappropriate production of proinflammatory cytokines. Janus kinase inhibitors (JAKi) can block the downstream pathway of many cytokines.
Tingyan He, Yu Xia, Ying Luo, Jun Yang
doaj +3 more sources
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis [PDF]
Frontiers in Pharmacology, 2016 Systemic juvenile idiopathic arthritis (sJIA) is the form of childhood arthritis whose treatment is most challenging. The demonstration of the prominent involvement of interleukin (IL)-1 in disease pathogenesis has provided the rationale for the treatment with biologic medications that antagonize this cytokine.
Angelo Ravelli +2 more
exaly +5 more sources
Systemic juvenile idiopathic arthritis in the pediatric practice of Donetsk region
Regulatory Mechanisms in Biosystems, 2023 Juvenile idiopathic arthritis with systemic onset is a special, rare and the most severe variant of juvenile idiopathic arthritis. The article analyzes the clinical features of the onset and course of juvenile idiopathic arthritis with systemic onset in ...
A. A. Koniushevska +5 more
doaj +1 more source
Revista Paulista de Pediatria, 2019 Objective: To highlight the importance of the new classification criteria for the macrophage activation syndrome (MAS) in systemic juvenile idiopathic arthritis in order to reduce morbidity and mortality outcome related to this disease.
Marina de Sousa Vieira +5 more
doaj +1 more source
Case Reports in Rheumatology, 2021 Systemic juvenile idiopathic arthritis (sJIA) is characterized by arthritis, fever, rash, lymphadenopathy, hepatosplenomegaly, and serositis. Macrophage activation syndrome is the most feared complication of sJIA with a high risk of mortality.
Nicole Davidson +5 more
doaj +1 more source
Reumatismo, 2023 Juvenile idiopathic arthritis (JIA) is the most common systemic disease causing uveitis in childhood and adolescence.
A. Martins +7 more
doaj +1 more source
Clinics, 2011 OBJECTIVE: To assess clinical and laboratory features that differentiate acute lymphoblastic leukemia from systemic juvenile idiopathic arthritis at disease onset. METHODS: Fifty-seven leukemia patients with musculoskeletal involvement, without blasts on
Mirian S. Tamashiro +5 more
doaj +1 more source